iZafe Group AB (publ) (IZAFE-B.ST)
SEK 0.21
(-0.93%)
SEK 0.21
(-0.93%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -32.17 Million SEK | -36.76% |
| 2022 | -23.52 Million SEK | 40.1% |
| 2021 | -39.27 Million SEK | -207.96% |
| 2020 | -12.75 Million SEK | 44.83% |
| 2019 | -23.11 Million SEK | -104.35% |
| 2018 | -11.31 Million SEK | -164.98% |
| 2017 | -4.26 Million SEK | 32.84% |
| 2016 | -6.35 Million SEK | -144.77% |
| 2015 | -2.59 Million SEK | 18.11% |
| 2014 | -3.17 Million SEK | 56.14% |
| 2013 | -7.22 Million SEK | -147.74% |
| 2012 | -2.91 Million SEK | 40.95% |
| 2011 | -4.94 Million SEK | 16.35% |
| 2010 | -5.9 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -4.95 Million SEK | -22.74% |
| 2024 Q1 | -5.6 Million SEK | 67.74% |
| 2024 Q2 | -4.03 Million SEK | 28.03% |
| 2023 Q1 | -5 Million SEK | 9.13% |
| 2023 Q3 | -4.82 Million SEK | 2.66% |
| 2023 Q2 | -4.95 Million SEK | 1.02% |
| 2023 Q4 | -17.38 Million SEK | -260.45% |
| 2023 FY | -32.17 Million SEK | -36.76% |
| 2022 Q2 | -5.28 Million SEK | 25.35% |
| 2022 FY | -23.52 Million SEK | 40.1% |
| 2022 Q3 | -5.82 Million SEK | -10.22% |
| 2022 Q1 | -7.07 Million SEK | 45.33% |
| 2022 Q4 | -5.51 Million SEK | 5.36% |
| 2021 Q2 | -8.25 Million SEK | 7.12% |
| 2021 Q4 | -12.94 Million SEK | -109.33% |
| 2021 Q1 | -8.89 Million SEK | 2.59% |
| 2021 FY | -39.27 Million SEK | -207.96% |
| 2021 Q3 | -6.18 Million SEK | 25.13% |
| 2020 Q2 | -5.31 Million SEK | 1.85% |
| 2020 Q1 | -5.41 Million SEK | 27.08% |
| 2020 Q4 | -9.12 Million SEK | -228.5% |
| 2020 FY | -12.75 Million SEK | 44.83% |
| 2020 Q3 | 7.1 Million SEK | 233.64% |
| 2019 Q2 | -6.45 Million SEK | -26.22% |
| 2019 FY | -23.11 Million SEK | -104.35% |
| 2019 Q3 | -4.13 Million SEK | 35.97% |
| 2019 Q4 | -7.42 Million SEK | -79.81% |
| 2019 Q1 | -5.11 Million SEK | -115.98% |
| 2018 Q2 | -4.1 Million SEK | -50.09% |
| 2018 FY | -11.31 Million SEK | -164.98% |
| 2018 Q1 | -2.73 Million SEK | -47.14% |
| 2018 Q3 | -2.1 Million SEK | 48.86% |
| 2018 Q4 | -2.36 Million SEK | -12.61% |
| 2017 Q2 | -807 Thousand SEK | -60.81% |
| 2017 Q3 | -1.09 Million SEK | -36.27% |
| 2017 Q4 | -1.86 Million SEK | -69.15% |
| 2017 FY | -4.26 Million SEK | 32.84% |
| 2017 Q1 | -501.82 Thousand SEK | -540.86% |
| 2016 Q3 | -852.61 Thousand SEK | 82.75% |
| 2016 FY | -6.35 Million SEK | -144.77% |
| 2016 Q2 | -4.94 Million SEK | -632.69% |
| 2016 Q1 | -674.59 Thousand SEK | -5.55% |
| 2016 Q4 | 113.83 Thousand SEK | 113.35% |
| 2015 Q4 | -639.13 Thousand SEK | 0.0% |
| 2015 Q2 | -659.22 Thousand SEK | 0.0% |
| 2015 Q1 | -659.22 Thousand SEK | 29.7% |
| 2015 FY | -2.59 Million SEK | 18.11% |
| 2015 Q3 | -639.13 Thousand SEK | 3.05% |
| 2014 FY | -3.17 Million SEK | 56.14% |
| 2014 Q4 | -937.69 Thousand SEK | -30.4% |
| 2014 Q2 | -730.85 Thousand SEK | 6.69% |
| 2014 Q1 | -783.23 Thousand SEK | 83.28% |
| 2014 Q3 | -719.08 Thousand SEK | 1.61% |
| 2013 Q3 | -432.55 Thousand SEK | 68.24% |
| 2013 FY | -7.22 Million SEK | -147.74% |
| 2013 Q4 | -4.68 Million SEK | -982.83% |
| 2013 Q1 | -750.28 Thousand SEK | 27.58% |
| 2013 Q2 | -1.36 Million SEK | -81.55% |
| 2012 Q2 | -551.4 Thousand SEK | 32.49% |
| 2012 FY | -2.91 Million SEK | 40.95% |
| 2012 Q1 | -816.81 Thousand SEK | 0.0% |
| 2012 Q4 | -1.03 Million SEK | -101.69% |
| 2012 Q3 | -513.68 Thousand SEK | 6.84% |
| 2011 FY | -4.94 Million SEK | 16.35% |
| 2010 FY | -5.9 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AddLife AB (publ) | 190 Million SEK | 116.934% |
| Biotage AB (publ) | 246 Million SEK | 113.079% |
| Bonesupport Holding AB (publ) | 245.02 Million SEK | 113.132% |
| Doxa AB (publ) | 291.9 Million SEK | 111.023% |
| Elekta AB (publ) | 1.3 Billion SEK | 102.471% |
| Ortivus AB (publ) | -18.24 Million SEK | -76.35% |
| Ortivus AB (publ) | -18.24 Million SEK | -76.35% |
| Q-linea AB (publ) | -229.36 Million SEK | 85.972% |
| S2Medical AB (publ) | -22.7 Million SEK | -41.694% |
| Synsam AB (publ) | 311 Million SEK | 110.346% |